General enquiries:

Product and licensing enquires:

Media / Investor enquiries via Walbrook PR: +44 (0) 20 7933 8780.

Please note that ReNeuron receives a large number of enquiries from interested parties regarding its technologies, therapeutic programmes and business operations. Whilst the Company will try to answer as many queries as it can, it has limited resources with which to do so and unfortunately may not be able to respond in all cases.

ReNeuron Group plc Head Office and Laboratories

ReNeuron, Pencoed Business Park, Pencoed, Bridgend, CF35 5HY

Telephone: +44 (0) 203 819 8400


ReNeuron regrets that it cannot advise or deal directly with individual patients or their physicians, relatives or friends concerning those patients’ medical conditions and the suitability of ReNeuron’s prospective stem cell therapies for treating them. Further information including relevant contact details, may be found on, a registry of clinical trials providing patients, family members, and members of the public free and easy access to information on clinical studies for a wide range of diseases and conditions, regarding:

PISCES Phase IIb clinical trial – a stroke study in patients with moderate to moderately severe disability as a result of an ischemic stroke (NCT03629275) please click here…

Phase I/II clinical trial investigating the Safety and Tolerability of Human Retinal Progenitor Cells (hRPC) in Patients with Retinitis Pigmentosa (RP) (NCT02464436) please click here

PISCES Phase II clinical trial investigating efficacy in upper arm paralysis post-stroke (NCT02117635), please click here

PISCES Phase I clinical trial investigating safety in disabled stroke patients (NCT01151124), please click here

OSIS (Observational Study in Ischaemic Stroke) non-interventional study of stroke patients (NCT01859572), please click here

Phase I clinical trial investigating safety in patients with lower limb ischaemia (NCT01916369), please click here